PHYSIOLOGIC FACTORS RELATED TO DRUG ABSORPTION:

INTRODUCTION

The systemic absorption of a drug is dependent on
(1) the physicochemical properties of the drug,
(2) the nature of the drug product, and
(3) the anatomy and physiology of the drug absorption site. All of these considerations are important in the manufacture and biopharmaceutic evaluation of drug products.

ROUTE OF DRUG ADMINISTRATION

Drugs may be given by parenteral, enteral, inhalation, transdermal (percutaneous), or intranasal route for systemic absorption. Each route of drug administration has certain advantages and disadvantages. Some characteristics of the more common routes of drug administration are listed in . The systemic availability and onset of drug action are affected by blood flow to the administration site, the physicochemical characteristics of the drug and the drug product, and by any pathophysiologic condition at the absorption site.
Many drugs are not administered orally because of drug instability in the gastrointestinal tract or drug degradation by the digestive enzymes in the intestine. For example, erythropoietin and human growth hormone (somatrophin) are administered intramuscularly, and insulin is administered subcutaneously or intramuscularly, because of the potential for degradation of these drugs in the stomach or intestine. Drug absorption after subcutaneous injection is slower than intravenous injection. Pathophysiologic conditions such as burns will increase the permeability of drugs across the skin compared with normal intact skin.

When a drug is administered by an extravascular route of administration (eg, oral, topical, intranasal, inhalation, rectal), the drug must first be absorbed into the systemic circulation and then diffuse or be transported to the site of action before eliciting biological and therapeutic activity. The general principles and kinetics of absorption from these extravascular sites follow the same principles as oral dosing, although the physiology of the site of administration differs.
NATURE OF CELL MEMBRANES

Many drugs administered by extravascular routes are intended for local effect. Other drugs are designed to be absorbed from the site of administration into the systemic circulation. For systemic drug absorption, the drug must cross cellular membranes. After oral administration, drug molecules must cross the intestinal epithelium by going either through or between the epithelial cells to reach the systemic circulation. The permeability of a drug at the absorption site into the systemic circulation is intimately related to the molecular structure of the drug and to the physical and biochemical properties of the cell membranes. Once in the plasma, the drug may have to cross biological membranes to reach the site of action. Therefore, biological membranes potentially pose a significant barrier to drug delivery.

*Transcellular absorption* is the process of drug movement across a cell. Some polar molecules may not be able to traverse the cell membrane but, instead, go through gaps or *tight junctions* between cells, a process known as *paracellular drug absorption*. shows the difference between the two processes. Some drugs are probably absorbed by a mixed mechanism involving one or more processes.
Membranes are major structures in cells, surrounding the entire cell (plasma membrane) and acting as a boundary between the cell and the interstitial fluid. In addition, membranes enclose most of the cell organelles (e.g., the mitochondrion membrane). Functionally, cell membranes are semipermeable partitions that act as selective barriers to the passage of molecules. Water, some selected small molecules, and lipid-soluble molecules pass through such membranes, whereas highly charged molecules and large molecules, such as proteins and protein-bound drugs, do not. Layers and the hydrophobic "tail" groups of the phospholipids aligned in the interior. The lipid bilayer theory explains the observation that lipid-soluble drugs tend to penetrate cell membranes more easily than polar molecules. However, the bilayer cell membrane structure does not account for the diffusion of water, small molecular-weight molecules such as urea, and certain charged ions.
The *fluid mosaic model*, explains the transcellular diffusion of polar molecules. According to this model, the cell membrane consists of globular proteins embedded in a dynamic fluid, lipid bilayer matrix. These proteins provide a pathway for the selective transfer of certain polar molecules and charged ions through the lipid barrier. As shown in , transmembrane proteins are interdispersed throughout the membrane. Two types of pores of about 10 nm and 50 to 70 nm were inferred to be present in membranes based on capillary membrane transport studies. These small pores provide a channel through which water, ions, and dissolved solutes such as urea may move across the membrane.
Theoretically, a lipophilic drug may pass through the cell or go around it. If the drug has a low molecular weight and is lipophilic, the lipid cell membrane is not a barrier to drug diffusion and absorption. **Passive diffusion** is the process by which molecules spontaneously diffuse from a region of higher concentration to a region of lower concentration. This process is passive because no external energy is expended. In, drug molecules move forward and back across a membrane. If the two sides have the same drug concentration, forward-moving drug molecules are balanced by molecules moving back, resulting in no net transfer of drug. When one side is higher in drug concentration, at any given time, the number of forward-moving drug molecules will be higher than the number of backward-moving molecules; the net result will be a transfer of molecules to the alternate side, as indicated in the figure by the big arrow. The rate of transfer is called flux, and is represented by a vector to show its direction in space. The tendency of molecules to move in all directions is natural, because molecules possess kinetic energy and constantly collide with one another in space. Only left and right molecule movements are shown in, because movement of molecules in other directions will not result in concentration changes because of the limitation of the container wall.
Passive diffusion is the major absorption process for most drugs. The driving force for passive diffusion is higher drug concentrations on the mucosal side compared to the blood. According to Fick's law of diffusion, drug molecules diffuse from a region of high drug concentration to a region of low drug concentration.

\[
\frac{dQ}{dt} = \frac{DAK}{h} (C_{GI} - C_p)
\]  

(13.1)

where \( \frac{dQ}{dt} \) = rate of diffusion, \( D \) = diffusion coefficient, \( K \) = lipid water partition coefficient of drug in the biologic membrane that controls drug permeation, \( A \) = surface area of membrane; \( h \) = membrane thickness, and \( C_{GI} \) and \( C_p \) = difference between the concentrations of drug in the gastrointestinal tract and in the plasma.

Because the drug distributes rapidly into a large volume after entering the blood, the concentration of drug in the blood initially will be quite low with respect to the concentration at the site of drug absorption. For example, a drug is usually given in milligram doses, whereas plasma concentrations are often in the microgram-per-milliliter or nanogram-per-milliliter range. If the drug is given orally, then \( C_{GI} \) \( C_p \) and a large concentration gradient is maintained, thus driving drug molecules into the plasma from the gastrointestinal tract.
Given Fick's law of diffusion, several other factors can be seen to influence the rate of passive diffusion of drugs. For example, the degree of lipid solubility of the drug influences the rate of drug absorption. The partition coefficient, $K$, represents the lipid water partitioning of a drug across the hypothetical membrane in the mucosa. Drugs that are more lipid soluble have a larger value of $K$. The surface area, $A$, of the membrane also influences the rate of absorption. Drugs may be absorbed from most areas of the gastrointestinal tract. However, the duodenal area of the small intestine shows the most rapid drug absorption, due to such anatomic features as villi and microvilli, which provide a large surface area. These villi are less abundant in other areas of the gastrointestinal tract.

The thickness of the hypothetical model membrane, $h$, is a constant for any particular absorption site. Drugs usually diffuse very rapidly through capillary plasma membranes in the vascular compartments, in contrast to diffusion through plasma membranes of capillaries in the brain. In the brain, the capillaries are densely lined with glial cells, so a drug diffuses slowly into the brain as if a thick lipid membrane existed. The term **blood brain barrier** is used to describe the poor diffusion of water-soluble molecules across capillary plasma membranes into the brain. However, in certain disease states such as meningitis these membranes may be disrupted or become more permeable to drug diffusion.
The diffusion coefficient, $D$, is a constant for each drug and is defined as the amount of a drug that diffuses across a membrane of a given unit area per unit time when the concentration gradient is unity. The dimensions of $D$ are area per unit time for example, cm\(^2\)/sec. Because $D$, $A$, $K$, and $h$ are constants under usual conditions for absorption, a combined constant $P$ or permeability coefficient may be defined.

$$P = \frac{DAK}{h}$$  \hspace{1cm} (13.2)

Furthermore, in Equation 13.1 the drug concentration in the plasma, $C_p$, is extremely small compared to the drug concentration in the gastrointestinal tract, $C_{GI}$. If $C_p$ is negligible and $P$ is substituted into Equation 13.1, the following relationship for Fick's law is obtained:

$$\frac{dQ}{dt} = P(C_{GI})$$  \hspace{1cm} (13.3)

Equation 13.3 is an expression for a first-order process. In practice, the extravascular absorption of most drugs tends to be a first-order absorption process. Moreover, because of the large concentration gradient between $C_{GI}$ and $C_p$, the rate of drug absorption is usually more rapid than the rate of drug elimination.

Many drugs have both lipophilic and hydrophilic chemical substituents. Those drugs that are more lipid soluble tend to traverse cell membranes more easily than less lipid-soluble or more water-soluble molecules. For drugs that act as weak electrolytes, such as weak acids and bases, the extent of ionization influences the rate of drug.
The ionized species of the drug contains a charge and is more water soluble than the nonionized species of the drug, which is more lipid soluble. The extent of ionization of a weak electrolyte will depend on both the pKa of the drug and the pH of the medium in which the drug is dissolved. *Henderson and Hasselbalch* used the following expressions pertaining to weak acids and weak bases to describe the relationship between pKa and pH:

For weak acids,

$$\text{Ratio} = \frac{[\text{salt}]}{[\text{acid}]} = \frac{[A^-]}{[HA]} = 10^{(pH-pK_a)} \quad (13.4)$$

For weak bases,

$$\text{Ratio} = \frac{[\text{base}]}{[\text{salt}]} = \frac{[\text{RNH}_2]}{[\text{RNH}_3^+]} = 10^{(pH-pK_b)} \quad (13.5)$$

$$\frac{[\text{salt}]}{[\text{acid}]} = 10^{(7.4 - 3.0)}$$

$$\log \frac{[\text{salt}]}{[\text{acid}]} = 7.4 - 3.0 = 4.4$$

$$\frac{[\text{salt}]}{[\text{acid}]} = 2.51 \times 10^4$$
In a simple system, the total drug concentration on either side of a membrane should be the same at equilibrium, assuming Fick's law of diffusion is the only distribution factor involved. **For diffusible drugs, such as nonelectrolyte drugs or drugs that do not ionize, the drug concentrations on either side of the membrane are the same at equilibrium.** However, for electrolyte drugs or drugs that ionize, the total drug concentrations on either side of the membrane are not equal at equilibrium if the pH of the medium differs on respective sides of the membrane. For example, consider the concentration of salicylic acid (pKa = 3.0) in the stomach (pH 1.2) as opposed to its concentration in the plasma (pH 7.4). According to the Henderson Hasselbalch equation (Eq. 13.4) for weak acids, at pH 7.4 and at pH 1.2, salicylic acid exists in the ratios that follow.

![Diagram showing the Henderson Hasselbalch equation for salicylic acid in gastric juice and plasma with pH values](image)
In the plasma, at pH 7.4:

\[ \text{Ratio} = \frac{(\text{RCOO}^-)}{\text{(RCOOH)}} = 2.51 \times 10^4 \]

In gastric juice, at pH 1.2:

\[ \text{Ratio} = \frac{(\text{RCOO}^-)}{\text{(RCOOH)}} = 10^{(1.2-3.0)} = 1.58 \times 10^{-2} \]

<table>
<thead>
<tr>
<th>DRUG</th>
<th>GASTRIC JUICE (pH 1.2)</th>
<th>PLASMA (pH 7.4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCOOH</td>
<td>1.0000</td>
<td>1</td>
</tr>
<tr>
<td>RCOO^-</td>
<td>0.0158</td>
<td>25100</td>
</tr>
<tr>
<td>Total drug concentration</td>
<td>1.0158</td>
<td>25101</td>
</tr>
</tbody>
</table>

Thus, **the pH affects distribution** of salicylic acid (RCOOH) and its salt (RCOO- ) across cell membranes. It is assumed that the acid, **RCOOH, is freely permeable and the salt, RCOO-, is not permeable across the cell membrane.** In this example the total concentration of salicylic acid at equilibrium is approximately 25,000 times greater in the plasma than in the stomach. These calculations can also be applied to weak bases, using Equation 13.5.
According to the **pH partition hypothesis**, if the pH on one side of a cell membrane differs from the pH on the other side of the membrane, then the drug (weak acid or base) will ionize to different degrees on respective sides of the membrane; the total drug concentrations (ionized plus nonionized drug) on either side of the membrane will be unequal; and the compartment in which the drug is more highly ionized will contain the greater total drug concentration. **For these reasons, a weak acid (such as salicylic acid) will be rapidly absorbed from the stomach (pH 1.2), whereas a weak base (such as quinidine) will be poorly absorbed from the stomach.**

Another factor that can influence drug concentrations on either side of a membrane is a particular **affinity** of the drug for a tissue component, which prevents the drug from moving freely back across the cell membrane. For example, a drug such as **dicumarol** binds to **plasma protein**, and **digoxin** binds to **tissue protein**. In each case, the protein-bound drug does not move freely across the cell membrane. Drugs such as **chlordane** are very **lipid soluble** and will **partition into adipose (fat) tissue**. In addition, a drug such as **tetracycline** might form a **complex with calcium** in the bones and teeth. Finally, a drug may concentrate in a tissue due to a specific uptake or active transport process. Such processes have been demonstrated for **iodide in thyroid tissue, potassium in the intracellular water, and certain catecholamines into adrenergic storage sites**. Such drugs may have a higher total drug concentration on the side where binding occurs, yet the free drug concentration that diffuses across cell membranes will be the same on both sides of the membrane.

**Instead of diffusing into the cell, drugs can also diffuse into the spaces around the cell as an absorption mechanism.** In **paracellular drug absorption**, drug molecules smaller than 500 MW diffuse into the tight junctions, or spaces between intestinal epithelial cells.
Carrier-Mediated Transport
Theoretically, a lipophilic drug may pass through the cell or go around it. If the drug has a low molecular weight and is lipophilic, the lipid cell membrane is not a barrier to drug diffusion and absorption. In the intestine, drugs and other molecules can go through the intestinal epithelial cells by either diffusion or a carrier-mediated mechanism. Numerous specialized carrier-mediated transport systems are present in the body, especially in the intestine for the absorption of ions and nutrients required by the body.

ACTIVE TRANSPORT
Active transport is a carrier-mediated transmembrane process that plays an important role in the gastrointestinal absorption and in renal and biliary secretion of many drugs and metabolites. A few lipid-insoluble drugs that resemble natural physiologic metabolites (such as 5-fluorouracil) are absorbed from the gastrointestinal tract by this process. Active transport is characterized by the transport of drug against a concentration gradient that is, from regions of low drug concentrations to regions of high concentrations. Therefore, this is an energy-consuming system. In addition, active transport is a specialized process requiring a carrier that binds the drug to form a carrier drug complex that shuttles the drug across the membrane and then dissociates the drug on the other side of the membrane.
The carrier molecule may be highly selective for the drug molecule. If the drug structurally resembles a natural substrate that is actively transported, then it is likely to be actively transported by the same carrier mechanism. Therefore, drugs of similar structure may compete for sites of adsorption on the carrier. Furthermore, because only a fixed number of carrier molecules are available, all the binding sites on the carrier may become saturated if the drug concentration gets very high. A comparison between the rate of drug absorption and the concentration of drug at the absorption site is shown in . Notice that for a drug absorbed by passive diffusion, the rate of absorption increases in a linear relationship to drug concentration. In contrast, when a drug is absorbed by a carrier-mediated process, the rate of drug absorption increases with drug concentration until the carrier molecules are completely saturated. At higher drug concentrations, the rate of drug absorption remains constant, or zero order.

![Graph showing rate of drug absorption vs concentration of drug](image)
FACILITATED DIFFUSION

Facilitated diffusion is also a carrier-mediated transport system, differing from active transport in that the drug moves along a concentration gradient (i.e., moves from a region of high drug concentration to a region of low drug concentration). Therefore, this system does not require energy input. However, because this system is carrier mediated, it is saturable and structurally selective for the drug and shows competition kinetics for drugs of similar structure. In terms of drug absorption, facilitated diffusion seems to play a very minor role.

CARRIER-MEDIATED INTESTINAL TRANSPORT

Various carrier-mediated intestinal systems (transporters) are present at the intestinal brush border and basolateral membrane for the absorption of specific ions and nutrients essential for the body. Many drugs are absorbed by these carriers because of the structural similarity to natural substrates. A transmembrane protein, P-glycoprotein (Pgp), has been identified in the intestine. Pgp appears to reduce apparent intestinal epithelial cell permeability from lumen to blood for various lipophilic or cytotoxic drugs. Other transporters are also present in the intestines. For example, many oral cephalosporins are absorbed through the amino acid transporter. Cefazolin, a parenteral-only cephalosporin, is not available orally because it cannot be absorbed to a significant degree through this mechanism.

Table 13.3 Intestine Transporters and Examples of Drugs
**Vesicular Transport**

Vesicular transport is the process of engulfing particles or dissolved materials by the cell. Pinocytosis and phagocytosis are forms of vesicular transport that differ by the type of material ingested. *Pinocytosis* refers to the engulfment of small solutes or fluid, whereas *phagocytosis* refers to the engulfment of larger particles or macromolecules, generally by macrophages. *Endocytosis* and *exocytosis* are the processes of moving specific macromolecules into and out of a cell, respectively. During pinocytosis or phagocytosis, the cell membrane invaginates to surround the material and then engulfs the material, incorporating it into the cell. Subsequently, the cell membrane containing the material forms a vesicle or vacuole within the cell.

**Vesicular transport is the proposed process for the absorption of orally administered Sabin polio vaccine and various large proteins.**
An example of exocytosis is the transport of a protein such as **insulin from insulin-producing cells of the pancreas into the extracellular space**. The insulin molecules are first packaged into intracellular vesicles, which then fuse with the plasma membrane to release the insulin outside the cell.

**Pore (Convective) Transport**

Very small molecules (such as **urea, water, and sugars**) are able to cross cell membranes rapidly, as if the membrane contained channels or pores. Although such pores have never been directly observed by microscopy, the model of drug permeation through aqueous pores is used to explain **renal excretion of drugs and the uptake of drugs into the liver**. A certain type of protein called a **transport protein** may form an open channel across the lipid membrane of the cell. Small molecules including drugs move through channel by diffusion more rapidly than at other parts of the membrane. the
Ion-Pair Formation
Strong electrolyte drugs are highly ionized or charged molecules, such as quaternary nitrogen compounds with extreme pKa values. **Strong electrolyte drugs maintain their charge at all physiologic pH values and penetrate membranes poorly.** When the ionized drug is linked up with an oppositely charged ion, an *ion pair* is formed in which the overall charge of the pair is neutral. This neutral drug complex diffuses more easily across the membrane. For example, the formation of ion pairs to facilitate drug absorption has been demonstrated for **propranolol, a basic drug that forms an ion pair with oleic acid, and quinine, which forms ion pair with hexylsalicylate.**

**ORAL DRUG ABSORPTION**
The oral route of administration is the most common and popular route of drug dosing. The oral dosage form must be designed to account for extreme pH ranges, the presence or absence of food, degradative enzymes, varying drug permeability in the different regions of the intestine, and motility of the gastrointestinal tract. In this chapter we will discuss intestinal variables that affect absorption; dosage-form considerations will be discussed in , , , and